Pasqualina D'ursi

Dr. Pasqualina D'ursi

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Research in Microbiology
Verified
Journal Article
Closed access
Martina CappellettiMartina Cappelletti
Martina Cappelletti
SFStefani Fedi
Stefani Fedi
JZJessica Zampolli
Jessica Zampolli
ALESSANDRA DI CANITOALESSANDRA DI CANITO
ALESSANDRA DI CANITO
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
PGPatrizia Di Gennaro
Patrizia Di Gennaro

1 November 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CBChiara Brullo
Chiara Brullo
RRRoberta Ricciarelli
Roberta Ricciarelli
JPJos Prickaerts
Jos Prickaerts
OAOttavio Arancio
Ottavio Arancio
MMMatteo Massa
Matteo Massa
OBOlga Bruno
Olga Bruno

Verified
Journal Article
Open access
PDF file
Naomi ScaranoNaomi Scarano
Naomi Scarano
Francesca MusumeciFrancesca Musumeci
Francesca Musumeci
BCBeatrice Casini
Beatrice Casini
Chiara BrulloChiara Brullo
Chiara Brullo
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
Elena CicheroElena Cichero
Elena Cichero
Alzheimer’s disease (AD) is a progressive, complex, multifactorial, neurodegenerative disease and accounts for most cases of dementia. The currently approved therapy includes cholinesterase inhibitors, NMDA-receptor antagonists and monoclonal antibodies. However, these medications were gradually discovered to be ineffective in removing the root of AD pathogenesis, having only symptomatic effects. Thus, the priority remains prevention and clarifying AD etiology. A better understanding of the neuroprotective mechanisms undertaken by specific genes is crucial to guide the design of novel therapeutic agents via selective ligands and precision medicine. In this review, we present a perspective of the physiological phase of the AD spectrum, of risk factors in AD with a focus on therapeutic approaches in three categories: neurotransmitters/ion modulations, peptide deposit control and aspecific treatments, followed by a discussion of treatment limitations. An overview of innovative strategies and non-pharmaceutical ancillary support is given.

8 March 2007 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
FMFrancesca Marino
Francesca Marino
ACAndrea Caprera
Andrea Caprera
LMLuciano Milanesi
Luciano Milanesi
EFElena M Faioni
Elena M Faioni
ERErmanna Rovida
Ermanna Rovida
Background: Activated Protein C (ProC) is an anticoagulant plasma serine protease which also plays an important role in controlling inflammation and cell proliferation. Several mutations of the gene are associated with phenotypic functional deficiency of protein C, and with the risk of developing venous thrombosis. Structure prediction and computational analysis of the mutants have proven to be a valuable aid in understanding the molecular aspects of clinical thrombophilia. Results: We have built a specialized relational database and a search tool for natural mutants of protein C. It contains 195 entries that include 182 missense and 13 stop mutations. A menu driven search engine allows the user to retrieve stored information for each variant, that include genetic as well as structural data and a multiple alignment highlighting the substituted position. Molecular models of variants can be visualized with interactive tools; PDB coordinates of the models are also available for further analysis. Furthermore, an automatic modelling interface allows the user to generate multiple alignments and 3D models of new variants. Conclusion: ProCMD is an up-to-date interactive mutant database that integrates phenotypical descriptions with functional and structural data obtained by computational approaches. It will be useful in the research and clinical fields to help elucidate the chain of events leading from a molecular defect to the related disease. It is available for academics at the URL http://www.itb.cnr.it/procmd/.

15 October 2009 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
FCFederica Chiappori
Federica Chiappori
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
IMIvan Merelli
Ivan Merelli
LMLuciano Milanesi
Luciano Milanesi
ERErmanna Rovida
Ermanna Rovida
Background: The design of mutants in protein functional regions, such as the ligand binding sites, is a powerful approach to recognize the determinants of specific protein activities in cellular pathways. For an exhaustive analysis of selected positions of protein structure large scale mutagenesis techniques are often employed, with laborious and time consuming experimental set-up. 'In silico' mutagenesis and screening simulation represents a valid alternative to laboratory methods to drive the 'in vivo' testing toward more focused objectives. Results: We present here a high performance computational procedure for large-scale mutant modelling and subsequent evaluation of the effect on ligand binding affinity. The mutagenesis was performed with a 'saturation' approach, where all 20 natural amino acids were tested in positions involved in ligand binding sites. Each modelled mutant was subjected to molecular docking simulation and stability evaluation. The simulated protein-ligand complexes were screened for their impairment of binding ability based on change of calculated Ki compared to the wild-type. An example of application to the Endothelial Protein C Receptor residues involved in lipid binding is reported. Conclusion: The computational pipeline presented in this work is a useful tool for the design of structurally stable mutants with altered affinity for ligand binding, considerably reducing the number of mutants to be experimentally tested. The saturation mutagenesis procedure does not require previous knowledge of functional role of the residues involved and allows extensive exploration of all possible substitutions and their pairwise combinations. Mutants are screened by docking simulation and stability evaluation followed by a rationally driven selection of those presenting the required characteristics. The method can be employed in molecular recognition studies and as a preliminary approach to select models for experimental testing.

6 August 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ALESSANDRA DI CANITOALESSANDRA DI CANITO
ALESSANDRA DI CANITO
JZJessica Zampolli
Jessica Zampolli
AOAlessandro Orro
Alessandro Orro
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
LMLuciano Milanesi
Luciano Milanesi
PGPatrizia Di Gennaro
Patrizia Di Gennaro
Bacteria belonging to the Rhodococcus genus play an important role in the degradation of many contaminants, including methylbenzenes. These bacteria, widely distributed in the environment, are known to be a powerhouse of numerous degradation functions, due to their ability to metabolize a wide range of organic molecules including aliphatic, aromatic, polycyclic aromatic compounds (PAHs), phenols, and nitriles. In accordance with their immense catabolic diversity, Rhodococcus spp. possess large and complex genomes, which contain a multiplicity of catabolic genes, a high genetic redundancy of biosynthetic pathways and a sophisticated regulatory network. The present study aimed to identify genes involved in the o-xylene degradation in R. opacus strain R7 through a genome-based approach. Using genome-based analysis we identified all the sequences in the R7 genome annotated as dioxygenases or monooxygenases/hydroxylases and clustered them into two different trees. The akb, phe and prm sequences were selected as genes encoding respectively for dioxygenases, phenol hydroxylases and monooxygenases and their putative involvement in o-xylene oxidation was evaluated. The involvement of the akb genes in o-xylene oxidation was demonstrated by RT-PCR/qPCR experiments after growth on o-xylene and by the selection of the R7–50 leaky mutant. Although the akb genes are specifically activated for o-xylene degradation, metabolic intermediates of the pathway suggested potential alternative oxidation steps, possibly through monooxygenation. This led us to further investigate the role of the prm and the phe genes. Results showed that these genes were transcribed in a constitutive manner, and that the activity of the Prm monooxygenase was able to transform o-xylene slowly in intermediates as 3,4-dimethylphenol and 2-methylbenzylalcohol. Moreover, the expression level of phe genes, homologous to the phe genes of Rhodococcus spp. 1CP and UPV-1 with a 90% identity, could explain their role in the further oxidation of o-xylene and R7 growth on dimethylphenols. These results suggest that R7 strain is able to degrade o-xylene by the Akb dioxygenase system leading to the production of the corresponding dihydrodiol. Likewise, the redundancy of sequences encoding for several monooxygenases/phenol hydroxylases, supports the involvement of other oxygenases converging in the o-xylene degradation pathway in R7 strain.